Larimar Therapeutics stock target raised to $14.89
An analyst price target for Larimar Therapeutics, Inc. was raised to $14.89 on a 12-month basis, according to the provided headline and FactSet reference data.
An analyst price target for Larimar Therapeutics, Inc. was raised to $14.89 on a 12-month basis, according to the provided headline and FactSet reference data.